Thanks for the commentary Tada. It was nice to see these publications highlight the novelty of Resverlogix's bromodomain selective molecules. As far as I know, Resverlogix is still the only company in the world with a bromodomain-2 selective BET inhibitor in clinical trials. Surely, other companies have bromodomain-selective compounds in their pre-clinical library. However, to go clinical a competitor would have to start in Phase 1 trials. Until that happens the clock really doesn't start ticking on the head start. It's quite possible that the patent expires for apabetalone prior to another competitor molecule coming to market. Quite the serendipitous discovery by the Resverlogix team to go from a small molecule with an unknown target that modulates apo-AI in a cell line screen.....to having the world's only bromodomain-2 selective BET inhibitor that has far-reaching cardioprotective effects beyond apo-AI/HDL modulation.

BearDownAZ